Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use

April 2003

Allergan is introducing Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use.

Restasis is approved for patients with chronic dry eye disease...also called keratoconjunctivitis sicca.

Chronic dry eye disease is caused by chronic inflammation, aging, or autoimmune disorders such as Sjögren's syndrome.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

which drug to use for the initial treatment of hypertension
Diabetes Do patients have to use Lantus (insulin glargine) at bedtime?
Diabetes Avandia (rosiglitazone) is now approved to be used with insulin in patients with type 2 diabetes
Natural Medicines anti-aging supplements that appear to contain growth hormone
Renal & Urology Oxytrol, the first PATCH for treating overactive bladder
Renal & Urology alpha-blockers for urinary problems in WOMEN
Vaccines CDC is promoting immunizations for ADULTS
Cardiology two new antihypertensives approved for NIGHTTIME dosing
Cardiology importance of using lower digoxin doses for heart failure
Cardiology rumor that enteric-coated aspirin doesn't work to prevent cardiovascular disease
Dermatology latest treatments for rosacea
caffeine might reduce the efficacy of methotrexate for rheumatoid arthritis
Ophthalmology Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use
new HIV drug, Fuzeon (enfuvirtide)
deadly pneumonia that's spreading from Asia to North America
Gastroenterology A new formulation of Kaopectate is creating confusion